These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 27497701)

  • 1. Expanded and armed natural killer cells for cancer treatment.
    Shimasaki N; Coustan-Smith E; Kamiya T; Campana D
    Cytotherapy; 2016 Nov; 18(11):1422-1434. PubMed ID: 27497701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.
    Barkholt L; Alici E; Conrad R; Sutlu T; Gilljam M; Stellan B; Christensson B; Guven H; Björkström NK; Söderdahl G; Cederlund K; Kimby E; Aschan J; Ringdén O; Ljunggren HG; Dilber MS
    Immunotherapy; 2009 Sep; 1(5):753-64. PubMed ID: 20636021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
    Matosevic S
    J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
    Michen S; Temme A
    Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Uncoupling of Canonical Phenotypic Markers and Functional Potency of
    Lieberman NAP; DeGolier K; Haberthur K; Chinn H; Moyes KW; Bouchlaka MN; Walker KL; Capitini CM; Crane CA
    Front Immunol; 2018; 9():150. PubMed ID: 29456538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
    Mehta RS; Rezvani K
    Front Immunol; 2018; 9():283. PubMed ID: 29497427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges of cancer therapy with natural killer cells.
    Klingemann H
    Cytotherapy; 2015 Mar; 17(3):245-9. PubMed ID: 25533934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
    Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
    J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.
    Suck G; Odendahl M; Nowakowska P; Seidl C; Wels WS; Klingemann HG; Tonn T
    Cancer Immunol Immunother; 2016 Apr; 65(4):485-92. PubMed ID: 26559813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
    Boissel L; Tuncer HH; Betancur M; Wolfberg A; Klingemann H
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):1031-1038. PubMed ID: 18721766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells.
    Burga RA; Nguyen T; Zulovich J; Madonna S; Ylisastigui L; Fernandes R; Yvon E
    Cytotherapy; 2016 Nov; 18(11):1410-1421. PubMed ID: 27421740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK cell-based immunotherapy for cancer.
    Fang F; Xiao W; Tian Z
    Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
    Kamiya T; Chang YH; Campana D
    Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy.
    Yang H; Tang R; Li J; Liu Y; Ye L; Shao D; Jin M; Huang Q; Shi J
    Cell Biochem Biophys; 2015 Dec; 73(3):723-9. PubMed ID: 27259316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of natural killer cells in cancer therapy and transplantation.
    Knorr DA; Bachanova V; Verneris MR; Miller JS
    Semin Immunol; 2014 Apr; 26(2):161-72. PubMed ID: 24618042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies.
    Heipertz EL; Zynda ER; Stav-Noraas TE; Hungler AD; Boucher SE; Kaur N; Vemuri MC
    Front Immunol; 2021; 12():732135. PubMed ID: 34925314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
    Hu W; Wang G; Huang D; Sui M; Xu Y
    Front Immunol; 2019; 10():1205. PubMed ID: 31214177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.